GlobeNewswire

TeraRecon Debuts Next Generation Northstar(TM) AI Explorer at SIIM18

Share

National Harbor, Maryland - May 31st, 2018, May 31, 2018 (GLOBE NEWSWIRE) -- TeraRecon (www.terarecon.com) today announced that its first-of-kind Northstar(TM) AI Explorer has reached a new milestone that allows physicians to interact with individual measurements, markings, and findings created by AI image processing algorithms. To demonstrate the potential of these AI-assisted workflows, the company is previewing an end-to-end cardiac MR analysis workflow in partnership with EnvoyAI (www.envoyai.com) and Corstem (www.corstem.ai) that provides highly automated results while keeping the physician informed and in control. The new Northstar features are the latest in a rapid progression of technological achievements made as the product evolves from a results viewer to a more powerful and integrated AI interaction and observation portal.

The new Northstar AI Explorer(TM) provides the ability to not only accept or reject certain images and reports created by AI, as Northstar has done previously, but now empowers physicians to fine-tune findings and interrogate the clinical assumptions that underlie the results in AI-generated reports. The system is composed of a web-based user interface that works seamlessly alongside or within the physicians' current PACS, EMR, and enterprise viewing systems.

The Northstar AI Explorer and the EnvoyAI platform together form an application framework upon which any 3rd party algorithm developer can build. "TeraRecon strives to make AI-assisted medical imaging interpretations more accessible to physicians by offering an unprecedented level of transparency into AI functionality along with deep integrations into existing workflows that optimize ease of use and efficiency. By exposing the key clinical assumptions that these AI machines are making and stopping to collect physician feedback before proceeding, we reduce risk while accelerating innovation and clinical adoption", said Jeff Sorenson, President and CEO of TeraRecon.

The cardiac MR analysis workflow prototype is composed of Corstem AI-generated anatomic contours and clinical assumptions being quickly verified or adjusted.  The physician feedback is sent to the Corstem application hosted on the EnvoyAI platform. The workflow then completes the cardiac function and fully quantitative pixel-wise perfusion analyses, marks updated findings in the images, and generates the report. The physician can make further adjustments and send the results to the permanent archive, such as the PACS or VNA.

"The most exciting aspect of the Northstar AI Explorer is that physicians can appreciate the quality of the AI findings", said Pascal Labrecque, Chief Operating Officer of Corstem. Pascal continued, "Our proprietary deep learning algorithm performs cardiac MR contouring with some of the most sophisticated motion correction technology available. The combination of TeraRecon's Northstar AI Explorer and the EnvoyAI platform allows cutting-edge AI technology to really shine."

The trained AI algorithms are not continuously learning from physician feedback in real-time, to ensure that tight version-control and testing regimens are maintained. However, with permission and appropriate data sharing protocols from the healthcare institution, their anonymized image data and physician ground truthing feedback may be shared and used by the algorithm developer to make improved versions.

Northstar was installed at its first beta-release customer site this month, Wake Radiology (www.wakerad.com) in Raleigh, North Carolina. "My expectation is that the Northstar viewer is going to simplify the experience for my radiologists. The output from these AI algorithms are expected to far surpass what we could generate individually on any given day, for specific reports. Volumetric measurements and serial comparisons that could not be done or would take a lot of time to do individually should be automated with AI", said Dr. William Way, Chief Medical Officer of Wake Radiology.  Dr. Way continued, "Having these results readily available and nicely integrated into our PACS and reporting workflows is vastly superior to what we are doing now."

"AI is important to where we are going as a radiology provider, and it is nice to be on the cutting edge", said Matt Dewey, Chief Information Officer of Wake Radiology.  Matt continued, "Because algorithms work differently and each of them has different inputs and outputs, my radiologists would otherwise have to have a different way of working with each one.  Northstar solves this problem by providing a simple and consistent way that our physicians work with the output of algorithms from many sources, and adapting itself to their personal preferences."

TeraRecon AI solutions will be demonstrated during the Society for Imaging Informatics in Medicine annual meeting, May 31st through June 2nd in National Harbor, Maryland at Booth #405. Online demonstrations and more information are available by contacting TeraRecon at info@terarecon.com.

About TeraRecon (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry's leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency.

About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor-neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. 

About Wake Radiology ( www.wakerad.com Founded in 1953, Wake Radiology is the leading provider of outpatient medical imaging in Central North Carolina. Its physicians have been trained as experts in specific imaging specialties - ranging from breast cancer detection and pediatrics to sports medicine and neuroradiology - to accurately diagnose healthcare issues. Another hallmark of Wake Radiology is its commitment to low-dose imaging and the elimination of unnecessary or duplicate exams. This approach strives to improve patient outcomes and reduces the overall cost of healthcare. Wake Radiology is the region's largest outpatient imaging practice with nearly 50 radiologists who perform close to 600,000 procedures each year. It is the first outpatient imaging provider in the Triangle to earn the American College of Radiology's prestigious Breast Imaging Center of Excellence designation. Wake Radiology is an independent, locally owned and physician-led practice that actively supports the local community.

About CorStem (www.corstem.ai) Corstem is a machine learning and artificial intelligence software developer specialized in medical imaging analysis and computer vision. Founded in 2016, its AI-powered tools are setting the standard in dynamic cardiac analysis. Corstem enables a whole new level of efficiency and automation for diagnosis aid to save valuable physician and patient time. 

IMPORTANT REGULATORY NOTICE: The TeraRecon Northstar and Corstem cardiac MR products mentioned herein are not for clinical use or sale at this time.

Press Inquiries US: 1-650-372-1100 | info@terarecon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire

About GlobeNewswire

GlobeNewswire



Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL)26.5.2020 22:30:00 CESTPressmeddelande

KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL) Aktieägarna i Hoylu AB (publ), org. nr 559084-6381 ("Bolaget") kallas härmed till Bolagets årsstämma torsdagen den 25 juni 2020, kl. 09.00 hos Eversheds Sutherland Advokatbyrå på Strandvägen 1 i Stockholm. Inregistrering inleds kl. 08.45. INFORMATION MED ANLEDNING AV COVID-19 Med anledning av COVID-19 kommer Bolaget att vidta vissa försiktighetsåtgärder inför årsstämman. För att minska risken för smittspridning kommer ingen förtäring eller dryck att erbjudas. Styrelsemedlemmar och Bolagets ledning kommer i möjligaste mån att närvara via elektronisk uppkoppling. Aktieägarna har möjlighet att närvara via ombud. DELTAGANDE En aktieägare som vill delta på årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken senast torsdagen den 18 juni 2020, och anmäla sitt deltagande senast torsdagen den 18 juni 2020, helst före kl. 16.00. Anmälan att delta på årsstämman ska ske via e-post till bolagsstamma@hoylu.com, via post till to Hoylu AB

Saniona meddelar utfall i optionsinlösen26.5.2020 18:15:00 CESTPressmeddelande

PRESSMEDDELANDE 26 maj 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 1, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 11 – 25 maj 2020 har innehavare av teckningsoptioner av serie TO 1 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 970 797 teckningsoptioner av serie TO 1, vilket motsvarar en nyttjandegrad om 65,61 procent. Saniona tillförs därmed cirka 24,3 MSEK före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 24,3 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 30 383 316 stycken och aktiekapitalet uppgå till 1 519 165,80 SEK. ”Vi är tacksamma fö

Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CESTPressmeddelande

Den 2 juni kl 14.00 presenterar​ ​Henrik Nittmar, VD i Corline Biomedical AB​ den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020​ där presentationen även i efterhand kommer finnas tillgänglig, s​amt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati

Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CESTPressmeddelande

Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare

ZetaDisplay lanserar teknologi partnerskap med Kastus26.5.2020 09:00:00 CESTPressmeddelande

Malmö –ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) lanserar ett nytt partnerskap med det irländska företaget Kastus® för att tillhandahålla dess patenterade antimikrobiella ytbeläggningsteknik. Den nya tekniken som utvecklats av Kastus® och snart kommer att integreras i ZetaDisplays produktportfölj har visat sig vara effektiv mot bakterier på ytor och kan appliceras på pekskärmar och displayer där flera användare kommer att dela dessa. Oberoende studier har visat upp till 99,99 procent av bakterierna och svampar inklusive antibiotikaresistenta superbakterier som MRSA och E. coli blev blockerade på skärmen. Laila Hede Jensen, Chief Commercial Officer för ZetaDisplay, förklarar: "Vi är i startgropen för att distribuera lösningen globalt som gör det möjligt för handeln, kontor och andra offentliga platser att minska riskerna för medarbetare och besökare som använder dessa lokaler. Ett stort problemområde är pekskärmar och hur de kan skyddas bättre mot överföring av bakterier. Detta nya

CellaVision AB: CellaVision publicerar årsredovisningen för 201926.5.2020 08:20:00 CESTPressmeddelande

Informationen lämnades för offentliggörande den 26 maj 2020, kl 08:20 CET CellaVision meddelar idag att årsredovisningen för 2019 finns tillgänglig på bolagets hemsida www.cellavision.se samt kan läsas via länken nedan. Bolaget har fattat beslut om att endast trycka 2019 års årsredovisning i en mindre upplaga i enlighet med bolagets miljöpolicy. För att begära en tryckt version vänligen kontakta CellaVision via bolagets hemsida. För ytterligare information vänligen kontakta: Zlatko Rihter, VD, CellaVision AB Tel: +46 (0)733-62 11 06 | Epost: zlatko.rihter@cellavision.se Om CellaVision CellaVision är ett innovativt, globalt medicinteknikföretag som utvecklar och säljer ledande system för rutinanalys av blod och andra kroppsvätskor inom sjukvården. Analyserna utgör ofta viktigt underlag för snabba och korrekta sjukdomsdiagnoser, tex vid infektioner och allvarliga cancersjukdomar. CellaVisions produkter rationaliserar manuellt laboratoriearbete, säkrar och stödjer effektiva arbetsflöden o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom